RDRonald W. Davis

Ronald W. Davis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ronald W. Davis has a total of 497 co-authors. Here are the top co-authors by number of shared publications:

  • Wenzhong Xiao

    Computational Research Center for Complex Chronic Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

    10 shared publications
  • Michael N. Mindrinos

    Stanford Genome Technology Center, Stanford University, Palo Alto, CA 94305

    8 shared publications
  • Julie Wilhelmy

    Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Collaborative Research Center at Stanford, Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, CA 94304

    6 shared publications
  • Nader Pourmand

    Department of Biomolecular Engineering, University of California, Santa Cruz, CA 95064, USA

    6 shared publications
  • Stefanie S. Jeffrey

    Department of Surgery, Stanford University School of Medicine, Stanford, USA

    5 shared publications
  • AmirAli H. Talasaz

    Stanford Genome Technology Center, Stanford University, Palo Alto, California, United States of America

    4 shared publications

Latest Publications

  • Open Access

    Dynamic and precise electromagnetic levitation of single cells

    by Malavika Ramarao, Victor Garcia-Gradilla, Mehmet Burcin Unlu, Ronald W. Davis, Naside Gozde Durmus

    The biophysical properties of single cells are crucial for understanding cellular function and behavior in biology and medicine. However, precise manipulation of cells in 3-D microfluidic environments remains challenging, particularly for heterogeneous populations. Here, we present “Electro-LEV,” a unique platform integrating electromagnetic and magnetic levitation principles for dynamic 3-D control of cell position during separation. We demonstrated that small current adjustments in electromagnets significantly alter the levitation heights of diverse particles and cell types. By periodically modulating and tracking cell positions along the z-axis, Electro-LEV identified distinct levitation behaviors between single cells and cell clusters, with clusters responding more rapidly to magnetic field changes. Furthermore, we demonstrated that Electro-LEV significantly enhances the purity and efficiency of levitational sorting, achieving 10-fold enrichment of live cells from 50% starting viability samples and 18.8-fold enrichment from 10% starting viability samples. These results establish Electro-LEV as a powerful tool for investigating cellular heterogeneity, differentiating cell sizes and types, and improving cell sorting efficiency. Thus, Electro-LEV is broadly applicable, offering different possibilities for high-resolution cell analysis and label-free cell sorting in various biomedical fields, including but not limited to single-cell sequencing and drug screening.


  • Top Cited Papers
    Open Access

    Patient-reported treatment outcomes in ME/CFS and long COVID.

    by Martha Eckey, Peng Li, Braxton Morrison, Jonas Bergquist, Ronald W Davis, Wenzhong Xiao

    Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID are persistent multisystem illnesses affecting many patients. With no known effective FDA-approved treatments for either condition, patient-reported outcomes of treatments may prove helpful in identifying management strategies that can improve patient care and generate new avenues for research. Here, we present the results of an ME/CFS and long COVID treatment survey with responses from 3,925 patients. We assess the experiences of these patients with more than 150 treatments in conjunction with their demographics, symptoms, and comorbidities. Treatments with the greatest perceived benefits are identified. Patients with each condition who participated in the study shared similar symptom profiles, including all the core symptoms of ME/CFS, e.g., 89.7% of ME/CFS and 79.4% of long COVID reported postexertional malaise (PEM). Furthermore, treatment responses between these two patient groups were significantly correlated (R2 = 0.68). Patient subgroups, characterized by distinct symptom profiles and comorbidities, exhibited increased responses to specific treatments, e.g., a POTS-dominant cluster benefiting from autonomic modulators and a cognitive-dysfunction cluster from CNS stimulants. This study underscores the symptomatic and therapeutic similarities between ME/CFS and long COVID and highlights the commonalities and nuanced complexities of infection-associated chronic diseases and related conditions. While this study does not provide recommendations for specific therapies, in the absence of approved treatments, insights from patient-reported experiences provide urgently needed real-world evidence for developing targeted patient care therapies and future clinical trials.


  • Top Cited Papers
    Open Access

    Oxidative stress is a shared characteristic of ME/CFS and Long COVID.

    by Vishnu Shankar, Julie Wilhelmy, Ellis J Curtis, Basil Michael, Layla Cervantes, Vamsee Mallajosyula, Ronald W Davis, Michael Snyder, Shady Younis, William H Robinson, et al.

    Over 65 million individuals worldwide are estimated to have Long COVID (LC), a complex multisystemic condition marked by fatigue, post-exertional malaise, and other symptoms resembling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). With no clinically approved treatments or reliable diagnostic markers, there is an urgent need to define the molecular underpinnings of these conditions. By studying bioenergetic characteristics of peripheral blood lymphocytes in 25 healthy controls, 27 ME/CFS, and 20 LC donors, we find both ME/CFS and LC donors exhibit signs of elevated oxidative stress, especially in the memory subset. Using a combination of flow cytometry, RNA-seq, mass spectrometry, and systems chemistry analysis, we observed aberrations in reactive oxygen species (ROS) clearance pathways including elevated glutathione levels, decreases in mitochondrial superoxide dismutase protein levels, and glutathione peroxidase 4-mediated lipid oxidative damage. Strikingly, these redox pathways changes show sex-specific trends. While ME/CFS females exhibit higher total ROS and mitochondrial calcium levels, males have normal ROS levels, with pronounced mitochondrial lipid oxidative damage. In females, these higher ROS levels correlate with T cell hyperproliferation, consistent with the known role of elevated ROS in initiating proliferation. This hyperproliferation can be attenuated by metformin, suggesting this Food and Drug Administration (FDA)-approved drug as a possible treatment, as also suggested by a recent clinical study of LC patients. Moreover, these results suggest a shared mechanistic basis for the systemic phenotypes of ME/CFS and LC, which can be detected by quantitative blood cell measurements, and that effective, patient-tailored drugs might be discovered using standard lymphocyte stimulation assays.


  • Open Access

    Tandem metabolic reaction–based sensors unlock in vivo metabolomics

    by Xuanbing Cheng, Zongqi Li, Jialun Zhu, Jingyu Wang, Ruyi Huang, Lewis W. Yu, Shuyu Lin, Sarah Forman, Evelina Gromilina, Sameera Puri, et al.

    Mimicking metabolic pathways on electrodes enables in vivo metabolite monitoring for decoding metabolism. Conventional in vivo sensors cannot accommodate underlying complex reactions involving multiple enzymes and cofactors, addressing only a fraction of enzymatic reactions for few metabolites. We devised a single-wall-carbon-nanotube-electrode architecture supporting tandem metabolic pathway–like reactions linkable to oxidoreductase-based electrochemical analysis, making a vast majority of metabolites detectable in vivo. This architecture robustly integrates cofactors, self-mediates reactions at maximum enzyme capacity, and facilitates metabolite intermediation/detection and interference inactivation through multifunctional enzymatic use. Accordingly, we developed sensors targeting 12 metabolites, with 100-fold-enhanced signal-to-noise ratio and days-long stability. Leveraging these sensors, we monitored trace endogenous metabolites in sweat/saliva for noninvasive health monitoring, and a bacterial metabolite in the brain, marking a key milestone for unraveling gut microbiota–brain axis dynamics.


  • Open Access

    Patient-Reported Treatment Outcomes in ME/CFS and Long COVID

    by Martha Eckey, Peng Li, Braxton Morrison, Ronald W Davis, Wenzhong Xiao

    Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID are persistent multi-system illnesses affecting many patients. With no known effective FDA-approved treatments for either condition, patient-reported outcomes of treatments are invaluable for guiding management strategies in patient care and generating new avenues for research. Here, we present the results of an ME/CFS and Long COVID treatment survey with responses from 3,925 patients. We assessed the experiences of these patients with more than 150 treatments, as well as their demographics, symptoms, and comorbidities. Patients with each condition who participated in the study shared similar symptom profiles, including all the core symptoms of ME/CFS, e.g., 89.7% of ME/CFS and 79.4% of Long COVID reported post-exertional malaise (PEM). Treatments with the greatest perceived benefits were identified, which had varied effects on different core symptoms. In addition, treatment responses were significantly correlated (R2 = 0.68) between the two patient groups. Patient subgroups with distinct profiles of symptoms and comorbidities showed varied responses to treatments, e.g., a POTS-dominant cluster benefiting from autonomic modulators and a cognitive-dysfunction cluster from CNS stimulants. This study underscores the symptomatic and therapeutic similarities between ME/CFS and Long COVID and highlights the commonalities and nuanced complexities of infection-associated chronic diseases and related conditions. Insights from patient-reported experiences, in the absence of approved treatments, provide urgently needed real-world evidence for targeted therapies in patient care and for developing future clinical trials. (Disclaimer: The findings presented in this paper are based on patient-reported information and are intended for research purposes only. They should not be interpreted as medical advice. Patients are advised to consult their healthcare provider before initiating or altering any treatment.)


  • Evaluation of the helium hermeticity reliability of copper through-glass vias

    by Chukwudi Okoro, Pamela Maurey, Ronald Davis, Scott Pollard


  • Open Access

    A touch-based multimodal and cryptographic bio-human–machine interface

    by Shuyu Lin, Jialun Zhu, Wenzhuo Yu, Bo Wang, Kiarash A. Sabet, Yichao Zhao, Xuanbing Cheng, Hannaneh Hojaiji, Haisong Lin, Jiawei Tan, et al.

    Significance: The awareness of the individuals’ biological status is critical for creating interactive environments. Accordingly, we devised a multimodal cryptographic bio-human–machine interface (CB-HMI), which seamlessly translates touch-based entries into encrypted biochemical, biophysical, and biometric indices (i.e., circulating biomarkers levels, heart rate, oxygen saturation level, and fingerprint pattern). As its central component, the CB-HMI features thin hydrogel-coated chemical sensors and a signal interpretation framework to access/interpret biochemical indices, bypassing the challenge of circulating analyte accessibility and the confounding effect of pressing force variability. Upgrading the surrounding objects with CB-HMI, we demonstrated new interactive solutions for driving safety and medication use, where the integrated CB-HMI uniquely enabled one-touch bioauthentication (based on the user’s biological state/identity), prior to rendering the intended services.


  • Open Access

    Modeling Brownian Microparticle Trajectories in Lab-on-a-Chip Devices with Time Varying Dielectrophoretic or Optical Forces

    by Mohammad Asif Zaman, Mo Wu, Punnag Padhy, Michael A. Jensen, Lambertus Hesselink, Ronald W. Davis

    Lab-on-a-chip (LOC) devices capable of manipulating micro/nano-sized samples have spurred advances in biotechnology and chemistry. Designing and analyzing new and more advanced LOCs require accurate modeling and simulation of sample/particle dynamics inside such devices. In this work, we present a generalized computational physics model to simulate particle/sample trajectories under the influence of dielectrophoretic or optical forces inside LOC devices. The model takes into account time varying applied forces, Brownian motion, fluid flow, collision mechanics, and hindered diffusion caused by hydrodynamic interactions. We develop a numerical solver incorporating the aforementioned physics and use it to simulate two example cases: first, an optical trapping experiment, and second, a dielectrophoretic cell sorter device. In both cases, the numerical results are found to be consistent with experimental observations, thus proving the generality of the model. The numerical solver can simulate time evolution of the positions and velocities of an arbitrarily large number of particles simultaneously. This allows us to characterize and optimize a wide range of LOCs. The developed numerical solver is made freely available through a GitHub repository so that researchers can use it to develop and simulate new designs.


  • Noninvasive wearable electroactive pharmaceutical monitoring for personalized therapeutics

    by Shuyu Lin, Wenzhuo Yu, Bo Wang, Yichao Zhao, Ke En, Jialun Zhu, Xuanbing Cheng, Crystal Zhou, Haisong Lin, Zhaoqing Wang, et al.

    To achieve the mission of personalized medicine, centering on delivering the right drug to the right patient at the right dose, therapeutic drug monitoring solutions are necessary. In that regard, wearable biosensing technologies, capable of tracking drug pharmacokinetics in noninvasively retrievable biofluids (e.g., sweat), play a critical role, because they can be deployed at a large scale to monitor the individuals’ drug transcourse profiles (semi)continuously and longitudinally. To this end, voltammetry-based sensing modalities are suitable, as in principle they can detect and quantify electroactive drugs on the basis of the target’s redox signature. However, the target’s redox signature in complex biofluid matrices can be confounded by the immediate biofouling effects and distorted/buried by the interfering voltammetric responses of endogenous electroactive species. Here, we devise a wearable voltammetric sensor development strategy—centering on engineering the molecule–surface interactions—to simultaneously mitigate biofouling and create an “undistorted potential window” within which the target drug’s voltammetric response is dominant and interference is eliminated. To inform its clinical utility, our strategy was adopted to track the temporal profile of circulating acetaminophen (a widely used analgesic and antipyretic) in saliva and sweat, using a surface-modified boron-doped diamond sensing interface (cross-validated with laboratory-based assays, R2 ∼ 0.94). Through integration of the engineered sensing interface within a custom-developed smartwatch, and augmentation with a dedicated analytical framework (for redox peak extraction), we realized a wearable solution to seamlessly render drug readouts with minute-level temporal resolution. Leveraging this solution, we demonstrated the pharmacokinetic correlation and significance of sweat readings. Significance To achieve the mission of personalized medicine, centering on delivering the right drug to the right patient at the right dose, therapeutic drug monitoring solutions are necessary. By devising a surface engineering strategy, we created a voltammetric sensing interface, featuring an “undistorted potential window,” within which the target electroactive drug’s voltammetric response is dominant and interference is eliminated, rendering reliable target quantification in noninvasively retrievable biofluids (sweat and saliva). Leveraging this sensing interface, a fully integrated, wearable solution was constructed to seamlessly render drug readouts with minute-level temporal resolution. To inform its clinical utility, the solution was utilized to demonstrate noninvasive pharmacokinetic monitoring of a pharmaceutical (here, acetaminophen, a widely used analgesic and antipyretic) in a wearable format.


  • Open Access

    Identification of polyketide biosynthetic gene clusters that harbor self-resistance target genes

    by Gergana A Vandova, Aleksandra Nivina, Chaitan Khosla, Ronald W Davis, Curt R Fischer, Maureen E Hillenmeyer

    Background: Polyketide secondary metabolites have been a rich source of antibiotic discovery for decades. Thousands of novel polyketide synthase (PKS) gene clusters have been identified in recent years with advances in DNA sequencing. However, experimental characterization of novel and useful PKS activities remains complicated. As a result, computational tools to analyze sequence data are essential to identify and prioritize potentially novel PKS activities. Here we exploit the concept of genetically-encoded self-resistance to identify and rank biosynthetic gene clusters for their potential to encode novel antibiotics. Results: To identify PKS genes that are likely to produce an antibacterial compound, we developed an automated method to identify and catalog clusters that harbor potential self-resistance genes. We manually curated a list of known self-resistance genes and searched all NCBI genome databases for homologs of these self-resistance genes in biosynthetic gene clusters. The algorithm takes into account (1) the distance of the potential self-resistance gene to a core enzyme in the biosynthetic gene cluster; (2) the presence of a duplicated housekeeping copy of the self-resistance gene; (3) the presence of close homologs of the biosynthetic gene cluster in diverse species also harboring the putative self-resistance gene; (4) evidence for coevolution of the self-resistance gene and core biosynthetic gene; and (5) self-resistance gene ubiquity. We generated a catalog of 190 unique PKS clusters whose products likely target known enzymes of antibacterial importance. We also present an expanded set of putative self-resistance genes that may be useful in identifying small molecules active against novel microbial targets. Conclusions: We developed a bioinformatic approach to identify and rank biosynthetic gene clusters that likely harbor self-resistance genes and may produce compounds with antibacterial properties. We compiled a list of putative self-resistance genes for novel antibacterial targets, and of orphan PKS clusters harboring these targets. These catalogues are a resource for discovery of novel antibiotics.